Table 2 Correlations between the expression of CCR8 on CD4+ TILs and the clinicopathologic characteristics of OC patients
From: CD4+CCR8+ Tregs in ovarian cancer: a potential effector Tregs for immune regulation
Clinical variables | CCR8low (%) | CCR8high (%) | PÂ value |
|---|---|---|---|
Sample size | 17 (51.5) | 16 (48.5) | Â |
Age (year) | |||
 < 50 years | 6 (46.2) | 7 (53.8) | 0.7283 |
 ≥ 50 years | 11 (55) | 9 (45) |  |
Tumor size (cm) | |||
 < 5 cm | 0 (0) | 0 (0) |  > 0.9999 |
 ≥  5 cm | 17 (51.5) | 16 (48.5) |  |
Histologic type | |||
 Serous carcinoma | 14 (58.3) | 10 (41.7) | 0.325 |
 Endometrioid cancer | 1 (50) | 1 (50) |  |
 Clear cell carcinom | 1 (16.7) | 5 (83.3) |  |
FIGO stage | |||
 I–II | 14 (66.7) | 7 (33.3) | 0.0324* |
 III–IV | 3 (25) | 9 (75) |  |
Differentiation | |||
 Well to moderate | 15 (68.2) | 7 (31.8) | 0.0104* |
 Poor | 2 (18.2) | 9 (81.8) |  |
Lymphatic metastasis | |||
 No | 5 (35.7) | 9 (64.3) | 0.1663 |
 Yes | 12 (63.2) | 7 (36.8) |  |
Distant metastasis | |||
 No | 3 (27.3) | 8 (72.7) | 0.0707 |
 Yes | 14 (63.6) | 8 (36.4) |  |
CA125 (U/mL) | |||
 < 200 U/mL | 3 (33.3) | 6 (66.7) | 0.2587 |
 ≥ 200 U/mL | 14 (58.3) | 10 (41.7) |  |
HE4 (pmol/L) | |||
 < 140 pmol/L | 5 (38.5) | 8 (61.5) | 0.296 |
 ≥ 140 pmol/L | 12 (60) | 8 (40) |  |
Ascites | |||
 No | 2 (28.6) | 5 (71.4) | 0.2245 |
 Yes | 15 (57.7) | 11 (42.3) |  |